Drug Type Small molecule drug |
Synonyms JNJ-MGLUR2-PAM, ADX 71149, JNJ-1813 + [1] |
Target |
Mechanism mGluR2 agonists(Metabotropic glutamate receptor 2 agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H25ClN2O |
InChIKeyHYOGJHCDLQSAHX-UHFFFAOYSA-N |
CAS Registry1127498-03-6 |
Start Date03 Nov 2022 |
Sponsor / Collaborator |
Start Date18 May 2021 |
Sponsor / Collaborator |
Start Date29 Jan 2021 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Seizures | Phase 2 | US | 18 May 2021 | |
Seizures | Phase 2 | BE | 18 May 2021 | |
Seizures | Phase 2 | DE | 18 May 2021 | |
Seizures | Phase 2 | PL | 18 May 2021 | |
Seizures | Phase 2 | RU | 18 May 2021 | |
Seizures | Phase 2 | KR | 18 May 2021 | |
Seizures | Phase 2 | ES | 18 May 2021 | |
Seizures | Phase 2 | UA | 18 May 2021 | |
Epilepsy | Phase 2 | CH | - | 27 Nov 2016 |
Depression | Phase 2 | BG | 01 Sep 2012 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |